Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PBH
STRONG BUYFLAGPrestige Consumer Healthcare Inc. · Healthcare · United States · $2.4B · Avg Vol: $32M/d
Prestige Consumer Healthcare has strong value V71 and quality Q59 with a buyback on file, but momentum at M44 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
Prestige Consumer Healthcare Inc. is a marketer and seller of over-the-counter (OTC) healthcare products, with a portfolio of well-known brands across categories like feminine care, oral care, and pain relief. The company benefits from its portfolio of established, often market-leading, niche OTC brands that command strong consumer loyalty and brand equity, providing stable cash flows and a durable competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 0.0% | 1.1B | 1.3B | 1.4B | 12.7% |
| EPS | 4.09 | -1.65 | 4.21 | 4.32 | 3.93 | -1.0% | 3.91 | 4.13 | 4.55 | 7.6% |
| Shares | 54.4M | 49.7M | 49.8M | 49.5M | 47.3M | -13.1% | 47.4M | — | — | — |
| Debt | 1.5B | 1.4B | 1.1B | 1.0B | 1.0B | -8.7% | 1.0B | — | — | — |
| Equity | 1.6B | 1.4B | 1.7B | 1.8B | 1.9B | 4.6% | — | — | — | — |
| Op CF | 259.9M | 229.7M | 248.9M | 251.5M | 257.6M | -0.2% | 257.6M | — | — | — |
| Inv CF | -256.5M | -11.6M | -20.1M | -17.5M | -136.8M | — | — | — | — | — |
| Fin CF | -7.6M | -185.8M | -241.0M | -182.1M | -156.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PBH | Prestige Consumer Healthcare Inc.(you) | $2.4B | 81 | STRONG BUY |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.4B | 88 | STRONG BUY |
| TRLV | Trulieve Cannabis Corp. | $1.6B | 89 | STRONG BUY |
| PAHC | Phibro Animal Health Corporation | $1.4B | 73 | BUY |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 93 | STRONG BUY |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.7B | 63 | HOLD |
| ANIP | ANI Pharmaceuticals, Inc. | $1.8B | 97 | STRONG BUY |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.7B | 87 | STRONG BUY |
| INDV | Indivior Pharmaceuticals, Inc. | $4.8B | 92 | STRONG BUY |
| AMPH | Amphastar Pharmaceuticals, Inc. | $825M | 75 | BUY |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.5%